Contrasting Abeona Therapeutics (ABEO) & Its Rivals

Abeona Therapeutics (NASDAQ: ABEO) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Abeona Therapeutics to related companies based on the strength of its profitability, valuation, analyst recommendations, dividends, earnings, institutional ownership and risk.

Profitability

This table compares Abeona Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Abeona Therapeutics -2,746.38% -26.66% -23.94%
Abeona Therapeutics Competitors -3,984.80% -117.96% -44.22%

Volatility and Risk

Abeona Therapeutics has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500. Comparatively, Abeona Therapeutics’ peers have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Abeona Therapeutics and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics 0 0 8 0 3.00
Abeona Therapeutics Competitors 474 2249 6143 119 2.66

Abeona Therapeutics presently has a consensus target price of $24.13, indicating a potential upside of 44.46%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.41%. Given Abeona Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Abeona Therapeutics is more favorable than its peers.

Earnings and Valuation

This table compares Abeona Therapeutics and its peers revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Abeona Therapeutics $842,999.00 -$23.80 million -27.38
Abeona Therapeutics Competitors $207.78 million -$2.31 million 0.51

Abeona Therapeutics’ peers have higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

38.4% of Abeona Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 6.8% of Abeona Therapeutics shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Abeona Therapeutics beats its peers on 7 of the 12 factors compared.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2017 Ticker Report. Google+.